Infections caused by antibiotic-resistant bacteria are a rising public health threat and make the identification of new antimicrobial strategy a priority. One such strategy is antibiotic repurposing. Auranofin is approved by the FDA as an orally administered drug for treating rheumatoid arthritis. Recently, auranofin has been reported to have potent antibacterial activity toward Clostridium difficile, Enterococcus faecium, Enterococcus faecalis, Treponema denticola, MRSA, replicating and non-replicating M. tuberculosis. We have synthesized a series of auranofin analogs. In this presentation, the synthesis of these compounds will be presented. The antibacterial activity of these compounds were tested against a panel of bacteria and results will also be presented.

Antibacterial activities of auraofin analogs

256th National Meeting (2018)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.